(1), we screened 65 of the 84 non-small cell lung cancer cell lines [9] against the irreversible EGFR/ERBB2 inhibitor BIBW2992 and the PI3K/mTOR inhibitor PI-103. Here, ERBB2 is linked to non-small cell lung carcinoma.